Anuh Pharma Ltd Valuation Shifts: From Very Attractive to Attractive Amid Sector Comparisons

Valuation Metrics: A Closer Look

As of 18 Aug 2026, Anuh Pharma’s price-to-earnings (P/E) ratio stands at 17.25, a figure that positions the stock favourably within the Pharmaceuticals & Biotechnology sector. This P/E is significantly lower than several key peers, including Ind-Swift Laboratories and Fredun Pharma, which trade at elevated multiples of 41.25 and 54.85 respectively. Such disparity highlights Anuh Pharma’s relative valuation advantage, particularly when considering its micro-cap status and growth prospects.

The price-to-book value (P/BV) ratio of 2.16 further supports this narrative of improved attractiveness. While not as low as some value-oriented stocks, it remains reasonable compared to the sector’s more expensive constituents. The enterprise value to EBITDA (EV/EBITDA) ratio of 10.55 also underscores a valuation that is more palatable than many competitors, with peers like Hester Biosciences and Shukra Pharmaceuticals trading at multiples exceeding 25 and 37 respectively.

Comparative Peer Analysis

When benchmarked against its peer group, Anuh Pharma’s valuation metrics reveal a stock that is attractively priced relative to industry heavyweights. For instance, TTK Healthcare, another attractive-rated stock, trades at a higher P/E of 21.01 and a notably higher EV/EBITDA of 26.41, suggesting that Anuh Pharma offers a more compelling entry point for investors seeking exposure to the pharmaceuticals sector without the premium valuation.

Conversely, several peers such as Jagsonpal Pharmaceuticals and NGL Fine Chem remain firmly in the expensive or very expensive categories, with P/E ratios above 30 and EV/EBITDA multiples well above 20. This contrast emphasises Anuh Pharma’s valuation appeal, especially for investors prioritising cost efficiency in their portfolio construction.

Financial Performance and Returns

Beyond valuation, Anuh Pharma’s operational metrics provide additional context. The company’s return on capital employed (ROCE) is a robust 16.65%, while return on equity (ROE) stands at 12.54%. These figures indicate efficient capital utilisation and a reasonable profitability profile, which underpin the stock’s attractive valuation grade.

Dividend yield at 1.97% adds a modest income component, enhancing the stock’s appeal for income-focused investors. However, the PEG ratio remains at zero, signalling either a lack of meaningful earnings growth projections or data unavailability, which investors should factor into their risk assessment.

Price Movement and Market Context

On the trading front, Anuh Pharma’s share price closed at ₹76.00 on 18 Aug 2026, down marginally by 0.34% from the previous close of ₹76.26. The stock’s 52-week high and low stand at ₹94.44 and ₹66.72 respectively, indicating a moderate trading range and some volatility over the past year.

Short-term returns have been under pressure, with a one-week decline of 2.05% and a one-month drop of 3.77%, both underperforming the Sensex benchmark which fell 1.04% and 0.54% respectively over the same periods. Year-to-date, Anuh Pharma’s stock has declined 5.57%, though this is less severe than the Sensex’s 8.79% fall, suggesting relative resilience.

Longer-term returns paint a more positive picture, with a three-year gain of 10.63% and a five-year appreciation of 23.22%. However, these figures lag the Sensex’s corresponding returns of 19.30% and 39.32%, reflecting the challenges faced by micro-cap pharmaceutical stocks in keeping pace with broader market indices.

Mojo Score and Rating Update

Anuh Pharma’s MarketsMOJO score currently stands at 42.0, reflecting a cautious stance on the stock. The company’s mojo grade was downgraded from Hold to Sell on 17 Aug 2026, signalling a more conservative outlook from the rating agency. This downgrade is likely influenced by the stock’s recent price underperformance and the competitive pressures within the pharmaceuticals sector.

Despite the downgrade, the valuation grade has improved from very attractive to attractive, indicating that while the stock may face near-term headwinds, its price levels offer a more compelling entry point than before. Investors should weigh this valuation improvement against the broader rating downgrade when considering portfolio allocation.

Sector and Industry Considerations

The Pharmaceuticals & Biotechnology sector continues to grapple with regulatory challenges, pricing pressures, and evolving market dynamics. Anuh Pharma’s micro-cap status adds an additional layer of volatility and risk, as smaller companies often face liquidity constraints and greater sensitivity to sector-specific developments.

Nonetheless, the company’s valuation metrics suggest it is better positioned than many peers to weather these challenges. Its EV to capital employed ratio of 2.37 and EV to sales of 0.91 are indicative of a relatively efficient capital structure and reasonable sales valuation, which may provide some cushion against sector headwinds.

Investor Takeaway

For investors seeking exposure to the pharmaceuticals sector, Anuh Pharma presents a nuanced opportunity. The stock’s valuation parameters have shifted favourably, offering an attractive price relative to earnings and book value compared to peers. However, the downgrade in mojo grade to Sell and recent price declines highlight the need for caution.

Long-term investors may find value in the company’s operational metrics and relative valuation, particularly if the broader sector stabilises. Short-term traders should remain vigilant to price volatility and sector developments that could impact performance.

Conclusion

Anuh Pharma Ltd’s recent valuation grade upgrade from very attractive to attractive reflects a subtle but important shift in price appeal, especially when viewed against its peer group and historical valuation levels. While the stock faces short-term challenges as evidenced by its mojo grade downgrade and recent price softness, its relative valuation metrics and solid return ratios provide a foundation for potential recovery.

Investors should balance the improved valuation against the company’s micro-cap risks and sector headwinds, considering their investment horizon and risk tolerance carefully. As always, a diversified approach and ongoing monitoring of sector developments will be key to navigating the evolving landscape of the Pharmaceuticals & Biotechnology industry.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →